Burning Rock Biotech Ltd Stock Price, News & Analysis

Burning Rock Biotech Limited (NASDAQ: BNR) announced its annual general meeting (AGM) scheduled for December 28, 2021, at its Shanghai office and in Hong Kong. Key proposals include the appointment of Ernst & Young Hua Ming LLP as the auditor for 2021, re-election of directors Yusheng Han, Gang Lu, and Shaokun Chuai, and approval of the 2021 Long-term Equity Incentive Plan. Shareholders on record by November 17, 2021, can attend the AGM. Details and the 2020 Annual Report are available on the Company’s investor relations website.

Burning Rock Biotech Limited (NASDAQ: BNR) announced Q3 2021 financial results, reporting revenues of RMB126.6 million (US$19.7 million), a 2.2% increase year-over-year. However, net loss widened to RMB170.5 million (US$26.5 million) from RMB127.1 million in the same quarter last year. The company signed pilot contracts for its 6-cancer early detection product, while anticipating a read-out for its 9-cancer product in H1 2022. Central laboratory revenue fell by 12.3% while in-hospital revenue surged 37.9%, highlighting a shift towards more in-hospital testing.

Burning Rock Biotech Limited (NASDAQ: BNR) announced a collaboration with IMPACT Therapeutics to provide testing services for the ATR inhibitor IMP9064, which has received IND clearance from the FDA for a Phase I/II clinical study in the U.S. The collaboration leverages Burning Rock's CLIA-certified labs in Guangzhou, China and California. IMP9064 shows high potency against ATR, suggesting a promising therapeutic window, especially in combination with Senaparib. This partnership supports Burning Rock's expansion in precision oncology and strengthens its capabilities in companion diagnostics.

Burning Rock Biotech Limited (NASDAQ: BNR) announced its plans to release unaudited financial results for Q3 2021 on November 16, 2021, prior to U.S. market opening. The company will hold a conference call at 8:00 a.m. ET to discuss the results. Burning Rock specializes in next generation sequencing (NGS) technology for precision oncology, claiming a leading market share in China with over 273,000 tests completed. Investors can access the earnings release via their investor relations website.

Burning Rock Biotech (NASDAQ: BNR) reported Q2 2021 revenues of RMB127.3 million (US$19.7 million), a 19.0% increase year-over-year. The company is focused on early cancer detection technology and plans to commercialize its 6-cancer early detection product in 2022, with contracts signing at six hospitals underway. However, operating expenses surged 93% to RMB292.3 million (US$45.3 million), leading to a net loss of RMB203.7 million (US$31.5 million). The company adjusted its 2021 revenue guidance to approximately RMB500 million, reflecting challenges from COVID-related testing impacts.

Burning Rock Biotech Limited (NASDAQ: BNR) has partnered with IMPACT Therapeutics to advance companion diagnostics (CDx) for the PARP inhibitor Senaparib, targeting prostate cancer. The partnership aims for global CDx submissions to the FDA and NMPA, leveraging Burning Rock's accredited labs in China and California. Senaparib is currently undergoing multiple clinical trials, including a Phase III trial for metastatic castration-resistant prostate cancer (mCRPC). This collaboration is expected to expedite clinical research, benefiting patients worldwide.

Burning Rock Biotech Limited (NASDAQ: BNR) will release its unaudited financial results for Q2 2021 on August 31, 2021, before the U.S. market opens. A conference call will follow at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, having completed over 273,000 tests. Burning Rock's focus includes NGS-based therapy selection and cancer early detection, which is in the clinical validation stage. Investors can access earnings results on their investor relations website.

Burning Rock Biotech (NASDAQ: BNR) reported Q1 2021 revenues of RMB106.6 million (US$16.3 million), up 58.4% from Q1 2020, but down 19.1% sequentially due to COVID-19 and seasonal impacts. Their central laboratory revenue rose 61.6% to RMB74.6 million (US$11.4 million), driven by a 64.9% increase in patient tests. However, net loss expanded to RMB171.4 million (US$26.2 million) from RMB52.6 million in Q1 2020. The company forecasts 2021 revenues at approximately RMB610 million (US$93.1 million), indicating 41.9% growth from 2020.

Burning Rock Biotech Limited (NASDAQ: BNR) has launched the PRESCIENT study, the first blood-based pan-cancer early-detection initiative in China using a multi-omics approach. This groundbreaking study will enroll 11,879 participants across 22 cancer types. The project aims to enhance the efficiency of cancer detection through liquid biopsy, promising improved patient outcomes. The study is backed by prominent experts from the National Cancer Center, who emphasize the necessity of advancing early detection technology in China to address rising cancer incidence and to provide clinical evidence for effective diagnostic tools.